Meanwhile, elevated disease-progression rate in the patients with PIK3CA mutant tumors than whole cohort (24.38%, p = 0.003, Fig. 1b), which indicated a poor chemotherapy response in PIK3CA mutant CRC. The gene discussed is PIK3CA; the disease is colorectal carcinoma.